CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 815,377 enrolled
Drug / intervention
Extra-fine hydrofluoroalkane-beclomethasone dipropionate +5 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01141439
NCT01141439N/ACompleted
CompareCT.gov

A Retrospective Evaluation of the Effectiveness and Cost-effectiveness of HFA-BDP MDI (Qvar®) Compared With CFC-BDP MDI and FP MDI Used in the Management of Asthma in a Representative UK UK Primary Care Population

Research in Real-Life Ltd·observational·Posted Jun 10, 2010·Updated Mar 14, 2013

In Brief

An observational study evaluating Extra-fine hydrofluoroalkane-beclomethasone dipropionate, Fluticasone propionate, and 3 other interventions for Asthma. Completed, enrolled 815,377 participants across 1 site.

Detailed Summary

The objective of the study was to compare the effectiveness, cost-effectiveness and direct healthcare costs of managing asthma in patients with evidence of persistent asthma, following the initiation and increased dose of inhaled corticosteroid (ICS) therapy using HFA-BDP (Qvar®) (either as initial therapy or as a step-up therapy) compared with the most commonly prescribed alternative ICS in the UK, CFC-beclometasone (BDP) and fluticasone (FP) as metered dose inhalers (MDIs). Qvar vs FP analyses were split between adults (12-60yrs) and paediatrics (5-11yrs).

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesUnited Kingdom
CollaboratorsTeva Branded Pharmaceutical Products R&D, Inc.

Timeline

N/ACompletedFinished
200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 10, 2010
Enrollment StartJan 1, 2001
Primary CompletionJun 1, 2007
Study CompletionJul 1, 2010
TodayJul 2, 2026
Enrollment to primary: 6.4 yearsPosted 16.1 years ago

Interventions

Extra-fine hydrofluoroalkane-beclomethasone dipropionatedrug

Initiation of HFA-BDP (any dose) in steroid naive patients via MDI

Extra-fine hydrofluoroalkane-beclomethasone dipropionatedrug

An increase in the baseline BDP-equivalent dose of inhaled corticosteroid as HFA-BDP via MDI

Fluticasone propionatedrug

An increase in the baseline BDP-equivalent dose of inhaled corticosteroid as FP via MDI

Beclomethasone dipropionatedrug

An increase in the baseline BDP-equivalent dose of inhaled corticosteroid as CFC-BDP via MDI

fluticasone propionatedrug

Initiation of FP (any dose) via MDI in steroid naive patient

Chlorofluorocarbon beclomethasone dipropionatedrug

Initiation of CFC-BDP (any dose) via MDI in steroid naive patient